Regenerative Materials for Surgical Reconstruction: Current Spectrum of Materials and a Proposed Method for Classification

Research output: Contribution to journalReview article

Abstract

Chronic wound management is an enormous economic strain and quality-of-life issue for patients. Current treatments are ineffective or expensive and invasive. Materials (native and artificial) can act as the basis to enhance wound repair but often fall short of complete healing. The therapeutic index of materials have often been enhanced by combining them with drug or biologic elution technologies. Combination of materials with living drugs (cells) presents a new paradigm for enhancing therapy. Cell material interaction and therapeutic output will depend on variables ascribed to the living drug as well as variables ascribed to the underlying matrix. In this article, we review medical matrices currently approved by the US Food and Drug Administration (FDA) that would likely be the first generation of materials to be used in this manner. Currently there are hundreds of different materials on the market. Identification of the right combinations would benefit from a classification scheme to group materials with similar composition or derivation. We provide a classification scheme and FDA documentation references that should provide researchers and clinicians a starting point for testing these materials in the laboratory and rapidly transitioning cell therapies to the bedside.

Original languageEnglish (US)
Pages (from-to)2099-2116
Number of pages18
JournalMayo Clinic proceedings
Volume94
Issue number10
DOIs
StatePublished - Oct 1 2019

Fingerprint

United States Food and Drug Administration
Pharmaceutical Preparations
Materials Testing
Wounds and Injuries
Therapeutics
Cell- and Tissue-Based Therapy
Cell Communication
Documentation
Economics
Quality of Life
Research Personnel
Technology

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Regenerative Materials for Surgical Reconstruction : Current Spectrum of Materials and a Proposed Method for Classification. / Sharma, Ayushman; Faubion, William Alvis; Dietz, Allan B.

In: Mayo Clinic proceedings, Vol. 94, No. 10, 01.10.2019, p. 2099-2116.

Research output: Contribution to journalReview article

@article{5867198b162745dd90f2bf7fbfb55c76,
title = "Regenerative Materials for Surgical Reconstruction: Current Spectrum of Materials and a Proposed Method for Classification",
abstract = "Chronic wound management is an enormous economic strain and quality-of-life issue for patients. Current treatments are ineffective or expensive and invasive. Materials (native and artificial) can act as the basis to enhance wound repair but often fall short of complete healing. The therapeutic index of materials have often been enhanced by combining them with drug or biologic elution technologies. Combination of materials with living drugs (cells) presents a new paradigm for enhancing therapy. Cell material interaction and therapeutic output will depend on variables ascribed to the living drug as well as variables ascribed to the underlying matrix. In this article, we review medical matrices currently approved by the US Food and Drug Administration (FDA) that would likely be the first generation of materials to be used in this manner. Currently there are hundreds of different materials on the market. Identification of the right combinations would benefit from a classification scheme to group materials with similar composition or derivation. We provide a classification scheme and FDA documentation references that should provide researchers and clinicians a starting point for testing these materials in the laboratory and rapidly transitioning cell therapies to the bedside.",
author = "Ayushman Sharma and Faubion, {William Alvis} and Dietz, {Allan B}",
year = "2019",
month = "10",
day = "1",
doi = "10.1016/j.mayocp.2019.03.013",
language = "English (US)",
volume = "94",
pages = "2099--2116",
journal = "Mayo Clinic Proceedings",
issn = "0025-6196",
publisher = "Elsevier Science",
number = "10",

}

TY - JOUR

T1 - Regenerative Materials for Surgical Reconstruction

T2 - Current Spectrum of Materials and a Proposed Method for Classification

AU - Sharma, Ayushman

AU - Faubion, William Alvis

AU - Dietz, Allan B

PY - 2019/10/1

Y1 - 2019/10/1

N2 - Chronic wound management is an enormous economic strain and quality-of-life issue for patients. Current treatments are ineffective or expensive and invasive. Materials (native and artificial) can act as the basis to enhance wound repair but often fall short of complete healing. The therapeutic index of materials have often been enhanced by combining them with drug or biologic elution technologies. Combination of materials with living drugs (cells) presents a new paradigm for enhancing therapy. Cell material interaction and therapeutic output will depend on variables ascribed to the living drug as well as variables ascribed to the underlying matrix. In this article, we review medical matrices currently approved by the US Food and Drug Administration (FDA) that would likely be the first generation of materials to be used in this manner. Currently there are hundreds of different materials on the market. Identification of the right combinations would benefit from a classification scheme to group materials with similar composition or derivation. We provide a classification scheme and FDA documentation references that should provide researchers and clinicians a starting point for testing these materials in the laboratory and rapidly transitioning cell therapies to the bedside.

AB - Chronic wound management is an enormous economic strain and quality-of-life issue for patients. Current treatments are ineffective or expensive and invasive. Materials (native and artificial) can act as the basis to enhance wound repair but often fall short of complete healing. The therapeutic index of materials have often been enhanced by combining them with drug or biologic elution technologies. Combination of materials with living drugs (cells) presents a new paradigm for enhancing therapy. Cell material interaction and therapeutic output will depend on variables ascribed to the living drug as well as variables ascribed to the underlying matrix. In this article, we review medical matrices currently approved by the US Food and Drug Administration (FDA) that would likely be the first generation of materials to be used in this manner. Currently there are hundreds of different materials on the market. Identification of the right combinations would benefit from a classification scheme to group materials with similar composition or derivation. We provide a classification scheme and FDA documentation references that should provide researchers and clinicians a starting point for testing these materials in the laboratory and rapidly transitioning cell therapies to the bedside.

UR - http://www.scopus.com/inward/record.url?scp=85071938106&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85071938106&partnerID=8YFLogxK

U2 - 10.1016/j.mayocp.2019.03.013

DO - 10.1016/j.mayocp.2019.03.013

M3 - Review article

C2 - 31515102

AN - SCOPUS:85071938106

VL - 94

SP - 2099

EP - 2116

JO - Mayo Clinic Proceedings

JF - Mayo Clinic Proceedings

SN - 0025-6196

IS - 10

ER -